Sarepta shares slide again as drugmaker bows to FDA pressure to pause gene therapy

Read all the articles in this bundle.

Sarepta shares slide again as drugmaker bows to FDA pressure to pause gene therapy

Sarepta Therapeutics’ stock slips further as company bows to FDA pressure to halt shipments